Field Medical Appoints Experienced Doctor Mark A. Turco as New CEO for Growth Strategy

Field Medical Welcomes Dr. Mark A. Turco as New CEO

Field Medical, Inc., a clinical-stage medical technology company known for developing advanced pulsed field ablation (PFA) solutions for complex cardiac arrhythmias, has officially announced the appointment of Dr. Mark A. Turco as its new Chief Executive Officer (CEO). This strategic decision reflects the company's ambition to elevate its growth trajectory and enhance its operational capabilities.

Dr. Turco's professional journey spans over three decades, during which he has amassed a wealth of experience in the cardiovascular sector, particularly within the realms of start-ups and established medical device companies. His robust background includes overseeing numerous clinical-stage enterprises, which has provided him with the insights necessary to lead organizations aimed at long-term scalability. His comprehensive expertise encompasses clinical trials and innovative product development, ensuring that Field Medical is well-positioned for success in the competitive medical technology landscape.

According to Ben Cannon, a board member at Field Medical and a leader in investment at BioStar Capital, "Dr. Turco’s unique experiences as a practicing cardiologist and seasoned medical device executive uniquely qualify him to steer Field Medical into its next growth phase. His proficiency will be instrumental as we accelerate our clinical programs and bolster our operational capabilities."

Dr. Turco previously held prestigious roles including President and CEO of JC Medical, Inc., where he spearheaded the development of a transcathéter aortic valve replacement system aimed at treating aortic regurgitation—a project that ultimately led to an acquisition by Edwards Lifesciences in July 2024. Furthermore, his tenure at Medtronic and Covidien allowed him to gain critical expertise as Medical Director for vascular and neurovascular franchises, steering advancements in medical technology.

“I am honored to join Field Medical at such a pivotal time in its evolution,” commented Dr. Turco. “The company has developed a differentiated PFA platform with the potential to significantly address the unmet needs of patients suffering from ventricular arrhythmias and atrial fibrillation. I look forward to collaborating closely with the remarkable Field Medical team to rigorously advance our clinical programs and navigate regulatory pathways, achieving our operational goals efficiently.”

About Field Medical, Inc.

Founded in 2022, Field Medical is dedicated to innovating PFA solutions for complex cardiac arrhythmias. The FieldForce ablation system integrates cutting-edge catheter design with proprietary FieldBending™ energy, aiming to deliver secure and effective ablation procedures with the goal of improving patient outcomes. The company reached a significant milestone in 2024 by receiving a breakthrough device designation and joining the FDA’s pilot program for its indication of ventricular tachycardia. Additionally, the VCAS trial results published in Circulation in October 2025 underline the relevance and promise of Field Medical's innovations.

For further information about Field Medical, visit their website at www.fieldmedicalinc.com and follow their updates on LinkedIn, X, and YouTube. Note that the FieldForce™ ablation system is an experimental device, limited by federal law to investigational use only.